Ije Nwokori Buys 202 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori acquired 202 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of GBX 74 per share, with a total value of £149.48.

Ije Nwokori also recently made the following trade(s):

• On Friday, June 12th, Ije Nwokori bought 112,500 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 76 per share, for a total transaction of £85,500.
• On Wednesday, May 13th, Ije Nwokori bought 233 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 64 per share, with a total value of £149.12.
• On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The stock was sold at an average price of GBX 66, for a total transaction of £134,673.66.
• On Tuesday, April 14th, Ije Nwokori purchased 232 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Price Performance

Shares of LON DOCS traded up GBX 0.40 during trading hours on Tuesday, hitting GBX 72.50. 377,685 shares of the stock were exchanged, compared to its average volume of 8,721,683. The company’s fifty day simple moving average is GBX 67.35 and its two-hundred day simple moving average is GBX 69.69. The company has a market cap of £693.89 million, a PE ratio of 30.21, a price-to-earnings-growth ratio of 6.40 and a beta of 0.25. The company has a debt-to-equity ratio of 108.27, a quick ratio of 1.13 and a current ratio of 2.61. Dr. Martens plc has a 1-year low of GBX 59.15 and a 1-year high of GBX 100.87.

Dr. Martens (LON:DOCS) last announced its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 EPS for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. The business had revenue of £764.90 million during the quarter. On average, sell-side analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on DOCS shares. Berenberg Bank dropped their price objective on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 100 target price on shares of Dr. Martens in a research note on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.